Niacin/lovastatin
drug combination
Niacin/lovastatin (trade names Advicor) was a drug combination used for the treatment of dyslipidemia. It was a combination of the lipid-modifying drug/vitamin niacin in extended release form and the statin drug lovastatin (trade name Mevacor). The combination preparation was developed by Kos Pharmaceuticals, Inc., which was acquired by Abbott Laboratories in 2006, subsequently transferred to AbbVie Inc. when that company was spun off from Abbott in January 2013.
Advicor was approved by the U.S. Food and Drug Administration (FDA) on December 17, 2001. The FDA withdrew approval on 18 April 2016. The reason given: "Based on the collective evidence from several large cardiovascular outcome trials (Refs. 1-3.), the Agency has concluded that the totality of the scientific evidence no longer supports the conclusion that a drug-induced reduction in triglyceride levels and/or increase in HDL-cholesterol levels in statin-treated patients results in a reduction in the risk of cardiovascular events." AbbVie Inc. agreed to voluntarily discontinue marketing Advicor. The same FDA action also applied to Simcor, a niacin-extended release combination with simvastatin.
Begin with the source’s own compact description: “Niacin/lovastatin” is drug combination. The dossier treats that line as a proposition to test through Niacin, lovastatin and drug, not as a finished interpretation.
Why this record matters
The phrase “drug combination” supplies a clear boundary for inquiry. It also exposes the unanswered questions: who defined that boundary, when it became stable and which sources sit outside it.
Named sources, stable identifiers and responsible institutions provide the strongest route from overview to verifiable evidence. The source revision retrieved here is dated May 29, 2025. The linked authority identifier is Q7023530. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2006, 2013, 2001 and 2016.
Overview language is designed for orientation and should not be treated as a substitute for the evidence cited beneath it. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Niacin/lovastatin”, its source revision and the description used here.
- Expand the search: follow Niacin/lovastatin primary sources, Niacin/lovastatin archive and Niacin research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Niacin/lovastatin”?
- Which institution is responsible for the underlying evidence?
- Which cited source is closest to the event, object or claim?
Search terms from this dossier
This entry incorporates text from “Niacin/lovastatin” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.